Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | Euronext Growth Oslo |
Sektor | Hälsovård |
Industri | Bioteknik |
2023-02-16 08:00:00
Oslo, 16 February 2023. Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX),
a Norwegian immuno-oncology company, today releases its fourth quarter and
second half 2022 results - Steady progress towards improving cancer treatment
outcomes.
"Our molecules have a unique dual mode of action and can kill cancer cells in a
way that activates a broad T-cell response with the potential to target all
cancer cells within heterogeneous tumors and thereby increasing the number of
patients responding to immunotherapy. We have seen very promising effects in
cancer patients so far and are eagerly looking forward to receiving the results
from the clinical Phase II studies with our lead candidate", says Dr. Øystein
Rekdal, CEO of Lytix Biopharma.
Highlights from the fourth quarter and second half 2022 and post period events:
* Business and Partnership:
o Verrica Pharmaceuticals recently completed treatment in Part 1 of their
ongoing Phase II study evaluating LTX-315 in basal cell carcinoma. Part 1 has
enrolled 10 patients and demonstrated a favorable safety and tolerability
profile with no reported serious adverse events. Patients receiving the higher
range of dosing experienced a consistent response of clinical tumor necrosis.
o Lytix Biopharma appointed Stephen Worsley as Chief Business Officer as part
of the company's strong focus on exploring commercial opportunities for its drug
candidates. Stephen brings a great track record of successful deals in oncology
on assets in development and is now introducing Lytix' assets to key opinion
leaders and companies within the industry.
* R&D:
o Following approval of the clinical trial application (CTA) for ATLAS-IT-05
in Europe in Q3 2022, the Phase II study in the US has expanded to an additional
three European countries